CHICAGO— Overall survival improved by more than two-thirds in patients with metastatic melanoma randomised to have GM-CSF added to their ipilimumab therapy. A phase II study in 245 previously treated patients — comparing the effect of ipilumumab with or without the growth factor — also found side effects were lower among those receiving the combination. At the American Society of Clinical Oncology’s 2013 meeting in Chicago, Sarah Maxwell heard from Dr. Stephen Hodi, Assistant Professor of Medicine at the Dana-Farber Cancer Institute/Harvard Cancer Center, Boston and Dr. Lynn Schuchter Chief of Hematolgy/Oncology at the Abramson Cancer Center, University of Pennsylvania, Philadelphia.
You may also like...
Audio Journal of Oncology in Advance – November 1st, 2006 1 Nov, 2006 Adjuvant Chemoradiotherapy: Big Gains In Pancreas Cancer 27 Jan, 2008 Postoperative chest node irradiation extends life in low relapse-risk breast cancer 9 Oct, 2013 MEK-inhibitor selumetinib doubles progression free survival in advanced uveal melanoma 13 Jun, 2013
- Previous story Normal stem cells are not depleted in acute myeloid leukaemia and could be targeted therapeutically
- Next story PD 1 inhibitor nivolumab shows promising activity in metastatic melanoma
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014